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Objective: Outcomes in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) did not differ between
carotid artery stenting (CAS) and carotid endarterectomy (CEA) for the composite primary end point of stroke, myocardial
infarction (MI), or death during the periprocedural period or ipsilateral stroke within 4 years. Rigorous credentialing and
training of interventionists, including vascular surgeons, were required for the randomization phase of CREST. Because the
lead-inphaseofCRESThad suggestedhigherperioperative risks afterCASperformedbyvascular surgeons, thepurposeof this
analysis was to examine differences in outcomes after randomization between CAS and CEA performed by vascular surgeons.
Methods: CREST is a prospective randomized controlled trial with blinded end point adjudication. Vascular surgeons
performed 237 (21%) of the CAS procedures and 765 (65%) of the CEA procedures among 2320 patients who received
their assigned treatment. Proportional hazards analyses were used to estimate the relative efﬁcacy of CAS vs CEA for
the composite primary end point and also for stroke and death.
Results: Among 2502 randomized patients, 1321 (53%) were symptomatic and 1181 (47%) were asymptomatic. For proce-
dures performed exclusively by vascular surgeons, the primary end point did not differ between CAS and CEA at 4-year
follow-up (6.2% vs 5.6%, respectively; hazard ratio [HR], 1.30; 95% conﬁdence interval [CI], 0.70-2.41; P[ .41) In this
subgroup, the periprocedural stroke and death rates were higher after CAS thanCEA for symptomatic patients (6.1% vs 1.3%;
P [ .01). Asymptomatic patients also had slightly higher stroke and death rates after CAS (2.6% vs 1.1%; P [ .20),
although this difference did not reach statistical signiﬁcance. Conversely, cranial nerve injuries (0.0% vs 5.0%; P < .001) were
less frequent after CAS than CEA. TheMI rates were slightly lower after CAS (1.3% vs 2.6%; P[ .24). In performing CAS,
vascular surgeons had outcomes for the periprocedural primary end point comparable to the outcomes of all interventionists
(HR, 0.99; 95%CI, 0.50-2.00) after adjusting for age, sex, and symptomatic status. Vascular surgeons also had similar results
after CEA for the periprocedural primary end point compared with other surgeons (HR, 0.73; 95% CI, 0.42-1.27).
Conclusions: When performed by surgeons, CAS and CEA have similar net outcomes, although the periprocedural
risks vary (lower stroke with CEA and lower MI with CAS). These data suggest that appropriately trained vascular
surgeons may safely offer both CEA and CAS for the prevention of stroke. The remarkably low stroke and death rates
after CEA performed by vascular surgeons in CREST, particularly among symptomatic patients, represent the best
outcomes ever reported after carotid interventions from a randomized controlled trial. ClinicalTrials.gov identiﬁer:
NCT0000473. (J Vasc Surg 2013;57:303-8.)Both carotid endarterectomy (CEA) and carotid artery Although CAS initially was reserved for patients with a high
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304 Timaran et al February 2013patients.6,10 In fact, comparisonof standard risk patients in the
Carotid Revascularization Endarterectomy versus Stenting
Trial (CREST) did not reveal any signiﬁcant differences
betweenCASandCEAfor theprimary endpoint.6,11Peripro-
cedural stroke, myocardial infarction (MI), or death and ipsi-
lateral strokeup to4 yearswere similarly low forbothCAS and
CEA, although a higher risk of stroke with CAS and a higher
risk of MI with CEA were observed. A planned meta-analysis
of European trials also failed to detect treatment differences
among symptomatic patients younger than 70 years.10
Certiﬁcation of surgeons and interventionists who per-
formed CAS and CEA in CREST was required prior to
randomizing patients.6,12 Although some interventionists
were certiﬁed after satisfactory evaluation of their endovas-
cular experience and CAS results, most underwent rigorous
hands-on training and auditing of their outcomes by partic-
ipation in the lead-in phase. Interestingly, the results of the
lead-in phase of CREST suggested higher perioperative
risks after CAS performed by vascular surgeons.12 Stroke,
death, and MI rates at 30 days by specialty in the lead-in
phase were 7.7% for vascular surgery, 6.7% for neurosur-
gery, 1.6% for neuroradiology, 6.6% for interventional radi-
ology, and 3.9% for interventional cardiology. After
adjustment for age, vascular surgeons had a twofold higher
event rate than interventional cardiologists (odds ratio,
2.05; 95% conﬁdence interval [CI], 1.18-3.56). Event rates
did not differ signiﬁcantly among other specialists.
The purpose of this study was to examine differences in
outcomes between CAS and CEA performed by vascular
surgeons in CREST. Speciﬁcally, data from the periproce-
dural period and up to 4 years were used to contrast the
results of CEA and CAS performed by vascular surgeons
and other specialists. Furthermore, the relative efﬁcacy of
the certiﬁcation and training process for all interventionists
was assessed.
METHODS
Details of the trial design and primary results of
CREST have been reported.6,11 CREST is a multicenter
randomized clinical trial with blinded end point adjudica-
tion that compared the safety and efﬁcacy of CAS vs
CEA in patients with carotid stenosis. Patients were
enrolled at 117 clinical centers in the United States and
Canada. Ethics review boards at participating centers
approved the protocol and informed consent, and all
patients gave written informed consent. To be eligible for
the study, symptomatic patients required $50% ipsilateral
carotid stenosis by angiography, $70% by duplex ultra-
sound scanning, or $70% by computed tomographic angi-
ography or magnetic resonance angiography if the stenosis
on ultrasound scan was 50% to 69%, whereas asymptomatic
patients needed $60% stenosis by angiography, $70% by
ultrasound scanning, or $80% by computed tomographic
angiography or magnetic resonance angiography if the
stenosis on ultrasound scan was 50% to 69%. Full eligibility
criteria have been reported.6,11
Patients randomized to CAS were treated with aspirin
and clopidogrel 48 hours before and for 30 days after theprocedure. The ACCUNET and ACCULINK carotid
stenting systems byAbbottVascular Solutions, Inc (formerly
Guidant; Santa Clara, Calif) were used for CAS procedures.
Patients who underwent CEA received aspirin at least 48
hours before and for 1 year or more after the procedure.
Full details of the procedures were reported elsewhere.13
Participating surgeons and interventionists were care-
fully selected by a well-documented process.12,14 Certiﬁca-
tion was achieved by 477 surgeons, who documented that
they had performed more than 12 procedures per year and
that the rates of complications and death were <3% among
asymptomatic patients and <5% among symptomatic
patients. The 224 certiﬁed interventionists had to demon-
strate experience in CAS with optimal results, receive
hands-on experience with the RX ACCULINK stent and
the RX ACCUNET embolic protection device, or partici-
pate in a lead-in phase prior to randomizing patients.
Most interventionists participated in the training program
and the lead-in phase. Only 73 of the initial 427 potential
applicants (17%) had clinical registry experience and satis-
factory results with the devices used in CREST and there-
fore were exempt from training and were approved for the
randomization phase.
Periprocedural neurologic evaluations were conducted
preprocedurally, at 24 to 48 hours postprocedurally, and at
1 month, 3 months, and annually. Cardiac enzyme levels
were obtained preprocedurally, at 24 to 48 hours postpro-
cedurally, and for chest pain lasting >15 minutes. Electro-
cardiograms were completed preprocedurally, 24 to 48
hours postprocedurally, and for chest pain lasting >15
minutes. Myocardial infarction was deﬁned as biomarker
elevation plus either chest pain or electrocardiographic
evidence of ischemia.
For the purpose of this study, similar statistical analyses
to those for the CREST primary results were used.6 On-
treatment end point analyses adjusting for major baseline
covariates were conducted using standard time-to-event
statistical modeling. In addition to the primary end point,
outcome differences among specialists were assessed for
components of the composite end point and periproce-
dural risk. Because this analysis was performed for a
subgroup of patients and only for those receiving therapy,
the comparison of CEA with CAS is not protected by
randomization. As such, differences between treatment
efﬁcacy for patients treated by CAS or CEA could be due
to the differential skills of the vascular surgeons for the
two procedures or alternatively due to differences in the
type of patients receiving CAS/CEA treatment. In order
to remove the potential effect of the latter source of differ-
ences, proportional hazards analysis was done, adjusting for
age, sex, and symptomatic status, the primary factors
shown to be associated with outcomes. Secondary aims
were analyzed by including interaction terms in the propor-
tional hazards models. For complication rates, the peripro-
cedural period was deﬁned according to the study protocol
as the 30-day period after the procedure. The absolute
differences in event proportions were calculated as the
percentage of patients with events.
Table I. Baseline characteristics of the study population





(N ¼ 765) P value
Age, mean (SD), years 68.5 (8.0) 69.4 (8.6) .13
Median 68.5 70.3 —
Interquartile range 11.1 12.7 —
Male gender, % 68.8 67.1 .62
White race, % 89.9 92.6 .19
Asymptomatic arteries, % 65.4 49.7 <.001
Risk factor, %
Hypertension 82.6 85.2 .33
Diabetes 26.7 29.5 .40
Dyslipidemia 79.2 84.0 .09










Severe ($70%) 91.6 87.2 .07
Anatomic characteristic
Left carotid artery treated 46.8 52.7 .12
Contralateral occlusion — — —
Procedural characteristic
Target lesion length, mean
(SD), mm
19.5 (8.8) — —
Median 19.5 — —
Interquartile range 12.0 — —
Total length of stented
segment, mean (SD), mm









Was it successfully delivered? 98.7 — —
General anesthesia, % — 84.8 —
Surgical technique, %
Patch — 80.7 —
Shunt — 59.1 —
CAS, Carotid artery stenting; CEA, carotid endarterectomy; SD, standard
deviation.
Sample sizes vary for speciﬁc characteristics (rows) because of missing data
on speciﬁc items for a small number of patients.
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Between December 21, 2000, and October 16, 2008,
176 vascular surgeons performed 1002 (43%) of the carotid
interventions among the 2320 patients who received their
assigned treatment in the randomization phase. Of these
interventions, vascular surgeons performed 237 of the
1136 CAS procedures (21%) and 765 of the 1184 CEAs
(65%). Among randomized patients who underwent carotid
interventions by vascular surgeons, 467 (46.6%) were symp-
tomatic and 535 (53.4%) were asymptomatic. As with the
entire CREST cohort, there were no signiﬁcant differences
in baseline characteristics between the CAS and CEA
patient groups, except for the percent asymptomatic CAS
patients compared with CEA patients (65.4% vs 49.7%)
and previous history of coronary artery disease or coronary
artery bypass graft surgery (39.3% vs 47.5%; Table I).
Among procedures performed by vascular surgeons,
embolic protection was used in 229 (98.7%) of the CAS
procedures, whereas for CEA general anesthesia and a patch
were used in 647 (84.8%) and 616 (80.7%), respectively.
Primary end point rates were not signiﬁcantly different
between CAS and CEA for procedures performed exclu-
sively by vascular surgeons at 4-year follow-up (6.2% vs
5.6%, respectively; hazard ratio [HR], 1.30; 95% CI,
0.70-2.41; P ¼ .41; Table II). These primary end point
rates were slightly lower than originally reported for CAS
vs CEA for the entire CREST cohort (7.2% vs 6.8%; HR,
1.11; 95% CI, 0.81-1.51; P ¼ .51). Similarly, the peripro-
cedural primary end point rates did not differ for CAS and
CEA (4.2% vs 3.8%, respectively; HR, 1.26; 95% CI, 0.61-
2.60; P ¼ .54). After the periprocedural period, the inci-
dence of ipsilateral stroke was similarly low after CAS and
CEA performed by vascular surgeons (2.1% and 1.8%,
respectively; P ¼ .63).
Among randomized patients who underwent the
assigned intervention performed by vascular surgeons, the
periprocedural stroke and death rates were higher after
CAS than CEA among symptomatic patients (6.1% vs
1.3%; HR, 4.84; 95% CI, 1.40-16.74; P ¼ .01) and among
asymptomatic patients (2.6% vs 1.1%; HR, 2.50; 95% CI,
0.63-9.99; P ¼ .20). Conversely, MI rates were lower for
CAS compared with CEA (1.3% vs 2.6%; P ¼ .24). As
expected, cranial nerve injuries (0.0% vs 5.0%) were less
frequent after CAS than CEA. Levels of signiﬁcance merit
conservative interpretation because of differences in number
of events (10 periprocedural stroke and death events for
symptomatic patients, eight stroke and death events for
asymptomatic patients, 12 MI events for symptomatic
patients, and 11 MI events in asymptomatic patients).
When vascular surgeons were compared with all other
specialists performing CAS, they had comparable outcomes
for the periprocedural primary end point (HR, 0.99; 95%
CI, 0.50-2.00) after adjusting for age, sex, and symptom-
atic status (Table III). Vascular surgeons also had similar
results after CEA for the periprocedural primary end point
compared with other specialists performing CEA (HR,
0.73; 95% CI, 0.42-1.27).DISCUSSION
The results of this substudy of CREST, the largest
randomized clinical trial comparing carotid interventions
for stroke prevention among conventional risk patients,
failed to detect differences in the primary end point of peri-
procedural stroke, death, and MI and ipsilateral stroke
thereafter between CAS and CEA performed by appropri-
ately trained vascular surgeons. As in the entire CREST
cohort, the periprocedural risks vary (lower stroke with
CEA and lower MI with CAS), which is predominantly
seen among patients with symptomatic carotid stenosis.6
Of note, the periprocedural stroke and death rates after
CEA performed by vascular surgeons for symptomatic
Table II. Treatment effect on time to ﬁrst primary end point, components of the primary end point, and other events for
vascular surgeons (n ¼ 1002)






















Overall 3 (1.3 6 0.7) 20 (2.6 6 0.6) 0.48a (0.14-1.62) .24
Symptomatic 2 (2.4 6 1.7) 10 (2.6 6 0.8) 0.93a (0.20-4.25) .93
Asymptomatic 1 (0.6 6 0.6) 10 (2.6 6 0.8) 0.25a (0.03-1.91) .18
Stroke and death end point




Overall 9 (3.8 6 1.2) 9 (1.2 6 0.4) 3.94 (1.53-10.10) .004 14 (6.2 6 1.6) 20 (3.1 6 0.7) 2.76 (1.37-5.55) .004
Symptomatic 5 (6.1 6 2.6) 5 (1.3 6 0.6) 4.84a (1.40-16.74) .013 6 (7.4 6 2.9) 13 (3.8 6 1.1) 2.45 (0.92-6.48) .07
Asymptomatic 4 (2.6 6 1.3) 4 (1.1 6 0.5) 2.50a (0.63-9.99) .20 8 (5.6 6 2.0) 7 (2.4 6 1.0) 3.10 (1.12-8.59) .03
Primary end point (any stroke,




Overall 10 (4.2 6 1.3) 29 (3.8 6 0.7) 1.26 (0.61-2.60) .54 14 (6.2 6 1.6) 39 (5.6 6 0.9) 1.30 (0.70-2.41) .41
Symptomatic 6 (7.3 6 2.9) 15 (3.9 6 1.0) 2.01 (0.78-5.20) .15 6 (7.3 6 2.9) 22 (6.1 þ 1.3) 1.36 (0.55-3.38) .50
Asymptomatic 4 (2.6 6 1.3) 14 (3.7 6 1.0) 0.75 (0.24-2.29) .62 8 (5.6 6 2.0) 17 (5.1 6 1.3) 1.25 (0.54-2.89) .61
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, conﬁdence interval; HR, hazard ratio; MI, myocardial infarction; SE, standard error.
aUnivariate proportional hazards model used because of the small number of events.
Table III. Periprocedural end points by treatment group for vascular surgeons compared with all other specialists
Periprocedural events

















Stroke and death end point
(any stroke or death within
periprocedural period)
Overall 9 (3.8 6 1.2) 40 (4.5 6 0.7) 1.12 (0.54-2.35) .76 9 (1.2 6 0.4) 16 (3.8 6 0.9) 0.32 (0.14-0.72) .006
Symptomatic 5 (6.1 6 2.6) 31 (6.1 6 1.1) 1.11 (0.43-2.86) .83 5 (1.3 6 0.6) 12 (5.0 6 1.4) 0.27a (0.09-0.76) .013
Asymptomatic 4 (2.6 6 1.3) 9 (2.4 6 0.8) 1.09a (0.33-3.52) .89 4 (1.1 6 0.5) 4 (2.2 6 1.1) 0.47a (0.12-1.87) .28
Primary end point (any stroke,
MI, or death within
periprocedural)
Overall 10 (4.2 6 1.3) 48 (5.4 6 0.8) 0.99 (0.50-2.0) .99 29 (3.8 6 0.7) 22 (5.3 6 1.1) 0.73 (0.42-1.27) .26
Symptomatic 6 (7.3 6 2.9) 35 (6.9 6 1.1) 1.19 (0.50-2.84) .70 15 (3.9 6 1.0) 16 (6.7 6 1.6) 0.59 (0.29-1.19) .14
Asymptomatic 4 (2.6 6 1.3) 13 (3.5 6 0.9) 0.74 (0.24-2.26) .59 14 (3.7 6 1.0) 6 (3.4 6 1.3) 1.09 (0.42-2.84) .86
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, conﬁdence interval; HR, hazard ratio; MI, myocardial infarction.
aUnivariate proportional hazards model employed because of the small number of events.
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intervention among symptomatic patients.
The periprocedural stroke and death rates for CAS and
CEA performed by vascular surgeons in CREST are the
lowest ever reported not only for interventions for symp-
tomatic carotid stenosis but also for asymptomatic carotid
disease (Figs 1 and 2). Moreover, both stroke and death
rates are well below the targets of 6% for symptomatic
patients and 3% for asymptomatic patients suggested in
recent treatment guideline statements.4,5,15
As reported in this study and the original CREST
publication, both CAS and CEA can be performed with
optimal periprocedural outcomes by experienced surgeonsand interventionists, including vascular surgeons.6 In many
instances, vascular surgeons potentially could offer both
procedures. Of note, CREST vascular surgeons were able
to perform CEA with a signiﬁcantly lower periprocedural
risk of stroke and death compared with surgeons and other
interventionists performing CAS. A higher MI rate with
CEA and the added risk of postoperative cranial nerve
palsies are still matters of concern. Fortunately, cranial
nerve palsies and MI did not have the same impact on
physical and mental health as stroke based on quality-of-
life assessment.6,16 The higher rate of periprocedural stroke
after CAS has fallen over time, as has the periprocedural
risk of stroke after CEA. The periprocedural risk of CAS
Fig 1. Perioperative stroke and death rate for carotid endarter-
ectomy in symptomatic patients. CAVATAS, Carotid and Verte-
bral Artery Transluminal Angioplasty Study17; CINC 1980,
Cincinnati 198018; CINC 1984, Cincinnati 198418; CREST,
Carotid Revascularization Endarterectomy versus Stenting Trial6;
CREST by VS, CREST by vascular surgeons; EVA-3S, Endarter-
ectomy versus Angioplasty in Patients with Symptomatic Severe
Carotid Stenosis trial19; ICSS, International Carotid Stenting
Study20; NASCET 1991, North American Symptomatic Carotid
Endarterectomy Trial21; NASCET 1998, North American Symp-
tomatic Carotid Endarterectomy Trial 199822; SPACE, Stent-
protected Angioplasty versus Carotid Endarterectomy trial.23
Fig 2. Perioperative stroke and death rate for carotid endarter-
ectomy in asymptomatic patients. ACAS, Asymptomatic Carotid
Atherosclerosis Study3; ACST, Asymptomatic Carotid Surgery
Trial24; CINC 1980, Cincinnati 198018; CINC 1984, Cincinnati
198418; CREST, Carotid Revascularization Endarterectomy versus
Stenting Trial6; CREST by VS, CREST by vascular surgeons.
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surgeons and interventionists from other specialties.
Interventionists’ training, experience, and specialty
have been suggested as important factors for optimal
outcomes after CAS procedures.12 In the CREST lead-in
phase, higher periprocedural event rates were seen for
procedures performed by vascular surgeons and marginally
higher rates for interventional radiologists compared with
cardiologists.12 These differences were attributed primarilyto experience with catheter-based therapies and particularly
CAS, and possibly to the complexity of the cases referred to
speciﬁc specialties rather than to the specialty itself.
Multivariate analyses of lead-in phase data were per-
formed in an attempt to adjust for potential confounders,
including symptomatic status, degree of stenosis, and age.
In these multivariate models, only age and interventionist
specialty remained signiﬁcant predictors of major adverse
events after CAS. After adjustment for age, vascular surgeons
had a higher event rate than did interventional cardiologists,
whereas event rates did not differ signiﬁcantly among inter-
ventional radiologists, neurosurgeons, and interventional
neuroradiologists. For the randomization phase, only inter-
ventionists with a proven track record and optimal results in
CAS techniques, irrespective of their specialty, were allowed
to perform carotid stenting.6
The reduced stroke and death rates in CREST, partic-
ularly for procedures performed by vascular surgeons, as
compared with previous trials and other specialists, may
reﬂect the effective surgeon credentialing in CEA, assimila-
tion of advanced endovascular technology, and rigorous
training and credentialing of interventionists performing
CAS. Although the certiﬁcation requirements were impor-
tant for patient safety, they limit the generalizability of the
results and conclusions to similarly qualiﬁed operators,
which constitutes one of the main limitations of CREST.
Of the 427 stent operators who applied for the trial, only
half (224 [52.4%]) ultimately were approved for the
randomization phase.12 The effects of experience in per-
forming carotid interventions or the number of cases per-
formed before the randomization on 30-day outcomes
could not be deﬁned with the available data and is beyond
the scope of this substudy. Total catheter experience, total
endovascular treatment experience, or total carotid treat-
ment experiences were not directly and objectively assessed
during the trial. The more experienced interventionists
were required to perform fewer cases in the lead-in phase
than the less experienced ones, making the beneﬁts of
experience more difﬁcult to detect from the lead-in phase
results. The potential inﬂuence of patient and operator
characteristics on the outcomes in CREST and other
randomized carotid intervention trials remains unknown
and warrants further investigation.
The stroke and death rates after CAS performed by
vascular surgeons were acceptable and within the targets
suggested by the American Heart Association/American
Stroke Association guidelines for the outcomes of carotid
interventions.7 However, the outcomes after CEA per-
formed by vascular surgeons were superior in terms of peri-
procedural stroke and death rates: 1.3% for symptomatic
patients and 1.1% for asymptomatic patients. These
improved outcomes after CEA in CREST may have several
implications. First, the remarkably low stroke and death
rates after CEA performed by vascular surgeons call for
a revision of the accepted periprocedural outcomes and
guidelines for carotid interventions. We suggest that the
guideline rates for periprocedural stroke and death of <6%
for symptomatic patients and <3% for asymptomatic
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current training and experience in both CAS and CEA are
well positioned to take care of patients with carotid disease
because they may be able to choose from among the
different options of treatment impartially and without bias.
Third, the improved outcomes with CEA in terms of stroke
and death call for improved outcomes with CAS. Better
outcomes following CAS may require improved systems
for embolic protection and stent design.
CONCLUSIONS
When performed by appropriately trained vascular
surgeons, CAS and CEA have similar net outcomes,
although the periprocedural risks vary (lower stroke with
CEA and lower MI with CAS). Trained vascular surgeons
may safely offer both CEA and CAS for the prevention
of stroke. As for all interventionists/operators, focus on
preventing periprocedural events is of high priority for
vascular surgeons. The remarkably low stroke and death
rates after CEA performed by vascular surgeons in CREST
represent the best outcomes ever reported after carotid
interventions from a randomized controlled trial.
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